Similar articles for PMID: 29568387

Year	Number of Results
2004	1
2005	1
2007	1
2008	1
2011	1
2012	2
2014	1
2015	9
2016	17
2017	7
2018	5
2019	2
2020	2
2021	3
2022	1
2023	1
2024	0

1

Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer.

Sun Q, Zhou S, Zhao J, Deng C, Teng R, Zhao Y, Chen J, Dong J, Yin M, Bai Y, Deng H, Wen J. Sun Q, et al. Oncotarget. 2018 Jan 10;9(17):13694-13705. doi: 10.18632/oncotarget.24122. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568387 Free PMC article.

2

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL. Haas AR, et al. Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30. Mol Ther. 2019. PMID: 31420241 Free PMC article. Clinical Trial.

3

Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Ko AH, et al. Mol Ther. 2020 Nov 4;28(11):2367-2378. doi: 10.1016/j.ymthe.2020.07.017. Epub 2020 Jul 21. Mol Ther. 2020. PMID: 32730744 Free PMC article.

4

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.

Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z. Maliar A, et al. Gastroenterology. 2012 Nov;143(5):1375-1384.e5. doi: 10.1053/j.gastro.2012.07.017. Epub 2012 Jul 20. Gastroenterology. 2012. PMID: 22819865

5

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Hillerdal V, Essand M. Hillerdal V, et al. BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. BioDrugs. 2015. PMID: 25859858 Free PMC article. Review.

6

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.

Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, Yang Q, Wang Y, Han W. Feng K, et al. Protein Cell. 2018 Oct;9(10):838-847. doi: 10.1007/s13238-017-0440-4. Epub 2017 Jul 14. Protein Cell. 2018. PMID: 28710747 Free PMC article. Clinical Trial.

7

Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.

He J, Zhang Z, Lv S, Liu X, Cui L, Jiang D, Zhang Q, Li L, Qin W, Jin H, Qian Q. He J, et al. Cell Immunol. 2018 Jul;329:31-40. doi: 10.1016/j.cellimm.2018.04.007. Epub 2018 Apr 30. Cell Immunol. 2018. PMID: 29859625

8

Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.

Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay JC, Toh HC, Connolly JE, Xu XH, Wang S. Ang WX, et al. Oncotarget. 2017 Feb 21;8(8):13545-13559. doi: 10.18632/oncotarget.14592. Oncotarget. 2017. PMID: 28088790 Free PMC article.

9

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

O'Hara M, Stashwick C, Haas AR, Tanyi JL. O'Hara M, et al. Immunotherapy. 2016;8(4):449-60. doi: 10.2217/imt.16.4. Immunotherapy. 2016. PMID: 26973126 Free PMC article. Review.

10

[Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].

Li SP, Urban FA, Macgregor JN, Hughes DP, McDonagh KT. Li SP, et al. Ai Zheng. 2004 Nov;23(11 Suppl):1370-5. Ai Zheng. 2004. PMID: 15566639 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

48 results

Results by year